### Ciclosporin

**Section:** 8. Immunomodulators and antineoplastics  >  8.1. Immunomodulators for non-malignant disease

<table>
<thead>
<tr>
<th>Indication</th>
<th>Failure or rejection of transplanted organs or tissues</th>
</tr>
</thead>
<tbody>
<tr>
<td>INN</td>
<td>Ciclosporin</td>
</tr>
<tr>
<td>Medicine type</td>
<td>Chemical agent</td>
</tr>
<tr>
<td>List type</td>
<td>Complementary</td>
</tr>
</tbody>
</table>

**Formulations**
- Parenteral > General injections > IV: 50 mg per mL in 1 mL ampoule concentrate for injection
- Oral > Liquid: 100 mg per mL (EMLc)
- Oral > Solid > capsule: 25 mg

**EML status history**
- First added in 1991 (TRS 825)
- Changed in 1999 (TRS 895)
- Changed in 2002 (TRS 914)
- Changed in 2003 (TRS 920)
- Changed in 2007 (TRS 950)
- Changed in 2009 (TRS 953)
- Changed in 2018 (TRS 983)
- Changed in 2023 (TRS 1049)

**Sex**
- All

**Age**
- Also recommended for children

**Therapeutic alternatives**
- The recommendation is for this specific medicine

**Patent information**
- Patents have expired in most jurisdictions
- Read more about patents.

**Wikipedia**
- Ciclosporin

**DrugBank**
- Ciclosporin (Cyclosporine)

---

**Summary of evidence and Expert Committee recommendations**

Following the review of the age-appropriateness of formulations on the EMLc, the Expert Committee recommended the addition of ciclosporin oral liquid 100 mg/mL to the EMLc.